Woman and Man | 18 years and more
- | Country :
- France
- | organs :
- Sang Hématologie - Autres
- | Specialty :
- Thérapies Ciblées
Extract
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with smouldering systemic, indolent systemic or cutaneous mastocytosis with handicap
Scientific Abstract
en cours d'intégration;